PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAlfacalcidol
Alfacalcidol
Alfacalcidol is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
aranespBiologic Licensing Application2019-01-30
pulmozymeBiologic Licensing Application2022-04-14
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A11: Vitamins
— A11C: Vitamin a and d, incl. combinations of the two
— A11CC: Vitamin d and analogues
— A11CC03: Alfacalcidol
M: Musculo-skeletal system drugs
— M05: Drugs for treatment of bone diseases
— M05B: Drugs affecting bone structure and mineralization
— M05BB: Bisphosphonates, combinations affecting bone structure and mineralization
— M05BB06: Alendronic acid and alfacalcidol, sequential
HCPCS
No data
Clinical
Clinical Trials
1042 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative painD010149—G89.1813151220
Secondary hyperparathyroidismD006962EFO_1001173—11410319
Vitamin d deficiencyD014808EFO_0003762E551—44918
HypertensionD006973EFO_0000537I102162617
Chronic renal insufficiencyD051436—N181249117
Chronic hepatitis cD019698EFO_0004220B18.22554116
Prostatic neoplasmsD011471—C612932115
Prostatic hyperplasiaD011470EFO_0000284N402—46315
GlaucomaD005901EFO_0000516H401126414
Ocular hypertensionD009798EFO_1001069H40.01253112
Show 140 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———3711—645
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.041213——26
NeoplasmsD009369—C80952——16
Covid-19D000086382—U07.1284—315
Sleep initiation and maintenance disordersD007319—F51.01—14—49
Myeloid leukemia acuteD015470—C92.0442——8
MelanomaD008545——422—18
InflammationD007249MP_0001845—111—57
AnemiaD000740HP_0001903D64.9131—16
Breast neoplasmsD001943EFO_0003869C50121—26
Show 104 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD002292EFO_0000376—55———7
Multiple sclerosisD009103EFO_0003885G3523——37
Parkinson diseaseD010300EFO_0002508G2013——26
Ulcerative colitisD003093EFO_0000729K5113——36
Inflammatory bowel diseasesD015212EFO_0003767—11——56
Crohn diseaseD003424EFO_0000384K50—1——45
Dental cariesD003731EFO_0003819K0211——35
Myelodysplastic syndromesD009190—D4633———4
ThalassemiaD013789EFO_1001996D5612——14
Ovarian neoplasmsD010051EFO_0003893C5633———4
Show 115 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.93———58
PharmacokineticsD010599——6————6
Drug interactionsD004347——4————4
PresbyopiaD011305—H52.43————3
Non-hodgkin lymphomaD008228—C85.92————2
HyperemiaD006940EFO_0003822H34.822————2
CoughD003371HP_0012735R051———12
Cocaine-related disordersD019970—F142————2
Orthostatic intoleranceD054971——1———12
PregnancyD011247EFO_0002950Z33.11———12
Show 47 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic painD059350HP_0012532—————66
OsteoarthritisD010003EFO_0002506M15-M19————33
NeuralgiaD009437EFO_0009430—————33
Nociceptive painD059226——————33
Peripheral nervous system diseasesD010523HP_0009830G64————22
PneumoniaD011014EFO_0003106—————22
Thyroid neoplasmsD013964EFO_0003841—————22
OsteomalaciaD010018EFO_1002027M83————22
Deep sedationD054810——————22
Sleep qualityD000089943——————22
Show 107 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAlfacalcidol
INNalfacalcidol
Description
Alfacalcidol is a member of the class of D3 vitamins that is calciol in which the hydrogen at the 1alpha position is replaced by a hydroxy group. It is an active metabolite of cholecalciferol, which performs important functions in regulation of the calcium balance and the bone metabolism. It has a role as a bone density conservation agent. It is a member of D3 vitamins, a seco-cholestane, a hydroxycalciol and a diol. It is functionally related to a calciol.
Classification
Small molecule
Drug classvitamin D analogs
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O
Identifiers
PDB—
CAS-ID41294-56-8
RxCUI—
ChEMBL IDCHEMBL1601669
ChEBI ID31186
PubChem CID5282181
DrugBankDB01436
UNII IDURQ2517572 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,218 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aranesp
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
921 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use